杭州阿诺生物医药科技有限公司 Adlai Nortye
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
Adlai Nortye Announces Appointment of Dr. Victoria Demby as Senior Vice President of Global Regulatory Affairs 2022-03-15 02:00
Adlai Nortye Announces Publication of Preclinical Research of AN3025 (anti-hTNFR2）in Frontiers in Immunology 2022-02-21 21:00
Adlai Nortye Announces Global License-out Agreement with Biotime for Several Products Including PD-L1 Inhibitor (AN4005) and Anti-hTNFR2 Antibody (AN3025) 2022-01-26 21:00
Adlai Nortye Announces First Patient Dosed in Phase I Clinical Trial of the orally available, small-molecule PD-L1 inhibitor AN4005 for Advanced Tumors 2022-01-06 01:00
Adlai Nortye Announces First Patient Dosed in Phase Ia Clinical Trial of AN2025 and AN0025 in Combination with atezolizumab for Advanced Solid Tumors 2021-09-08 11:04
Adlai Nortye Announces First Patient Dosed in Global Phase III Clinical Trial of Buparlisib (AN2025) in Combination with Paclitaxel for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma 2021-04-15 09:00
Adlai Nortye Announces Formation of its New Scientific Advisory Board 2021-03-08 09:00
Adlai Nortye Announces First Patient Dosed in Phase 1b Clinical Trial of AN0025 (EP4 Antagonist) in Combination with Merck's KEYTRUDA® (pembrolizumab) for Advanced Solid Tumors 2020-08-24 13:13
Adlai Nortye Presents Encouraging Phase 1b Study Data of AN0025 (an Oral EP4 Antagonist) for Locally Advanced Rectal Cancer at ESMO 2019 2019-09-30 13:41
Adlai Nortye Receives NMPA Approval for Pelareorep (AN1004) in China to Initiate Phase III Clinical Trials 2019-03-21 18:21
Adlai Nortye's Buparlisib (AN2025) Set to Become a Potential Treatment for Anti-PD-1 Non-responding Tumor in HNSCC 2019-03-15 17:06
Adlai Nortye Announces Clinical Collaboration with Merck to Evaluate Adlai Nortye's AN0025 (EP4 Antagonist) in Combination with KEYTRUDA® (pembrolizumab) in Patients with Solid Tumors 2019-01-03 16:00
Adlai Nortye Opens New US Headquarters, Solidifying its Position in the Global Pharma Industry 2018-09-25 22:05
Adlai Nortye Eyes Global Expansion With the Opening of Its First International Site in USA 2018-08-16 22:00
Adlai Nortye Announces Engagement of Lars E. Birgerson, M.D., Ph.D., as CDO and President/CEO of Adlai Nortye USA 2018-08-07 01:15
Adlai Nortye announces the publication of the Biomarker Analysis From BERIL-1, the Buparlisib study in HNSCC 2018-07-30 11:12
Adlai Nortye Announce Global License Agreement for Buparlisib (BKM120) 2018-07-10 21:15
Adlai Nortye Raises $53M in Series B 2018-07-05 19:44
1